<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28684/most-anticipated-trial-results-regarding-biomarkers-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Most Anticipated Trial Results Regarding Biomarkers in RCC

Name: Most Anticipated Trial Results Regarding Biomarkers in RCC
Uploaded: 2019-07-02T07:15:53
Duration: 1 min 27 s
Description: Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).

00:01:27

Don

3 lat 431 Wyświetleń

Udostępnij Dodaj do Raport 0 0

Osadź (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28684/most-anticipated-trial-results-regarding-biomarkers-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Osadź (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28684/most-anticipated-trial-results-regarding-biomarkers-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28684/most-anticipated-trial-results-regarding-biomarkers-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28684?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190702191553_e03a/video_190702191553_e03a.jpg?cache=15669160731682794628">Most Anticipated Trial Results Regarding Biomarkers in RCC</a>

Link (BBCode):

[url=https://oncologytube.com/v/28684?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190702191553_e03a/video_190702191553_e03a.jpg?cache=15669160731682794628[/img]Most Anticipated Trial Results Regarding Biomarkers in RCC[/url]

Zaloguj się teraz !

Stały link

Przyjazny URL (SEO)

Aktualny czas (SEO)

Kategoria:

Kidney

Opis:

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).